14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
As of Apr 24, 2026, Amicus Therapeutics, Inc (FOLD) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas FOLD carries 59.4/100 (HOLD) at $14.49 (17.7x Forward P/E, 8.6% operating margin).
Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. FOLD 59.4/100 HOLD), FOLD captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.6% vs. 0.0% operating margin) and revenue trajectory (+23.7% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs FOLD. Trailing 12-month operating profitability (AKRO 0.0% vs FOLD 8.6%) and valuation multiples (AKRO N/M vs FOLD 17.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $4.5B market capitalization and 8.6% operating margin.
OpEx & R&D Reinvestment79.9% of Rev ($507M)
90D Engineering Disclosures0 Published
Investor FAQ AKRO vs FOLD Key Questions & Quantitative Answers
As of Apr 24, 2026, Amicus Therapeutics, Inc (FOLD) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas FOLD carries 59.4/100 (HOLD) at $14.49 (17.7x Forward P/E, 8.6% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. FOLD 59.4/100 HOLD), FOLD captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.6% vs. 0.0% operating margin) and revenue trajectory (+23.7% vs. +0.0% YoY).
FOLD leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FOLD at +23.7% YoY revenue growth and -95.5% YoY earnings growth on $634M TTM revenue (88.5% gross margin, 8.6% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $634M for FOLD. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus 79.9% of Rev ($507M) (0 disclosures) for FOLD.
FOLD screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FOLD trades at 17.7x Forward P/E, 30.5x Trailing P/E, N/M PEG, and 7.2x EV/Revenue (6.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus FOLD (-11.6% ROE) capital efficiency.
In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, FOLD carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Apr 24, 2026. For educational research only; not investment advice.